David C. Hastings

CIK: 0001237401

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (20.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (80.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

SCYX

SCYNEXIS INC

TRVI

Trevi Therapeutics, Inc.

Officer

ABUS

Arbutus Biopharma Corp

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

SCYX
SCYNEXIS INC
Jun 26, 2026
Award(A)
Direct
2.9K shares-
TRVI
Trevi Therapeutics, Inc.
Jan 8, 2026
Award(A)
Stock Option (right to buy)
Direct
375K shares-
SCYX
SCYNEXIS INC
Jun 26, 2025
Award(A)
Direct
23K shares-
ABUS
Arbutus Biopharma Corp
Feb 14, 2025
Award(A)
Direct
90.1K shares-
ABUS
Arbutus Biopharma Corp
Feb 4, 2025
Sale(S)
Direct
22.2K shares at avg. $3.28$73K

		Type	Shares	Price		Ownership
Jun 26, 2026	SCYX SCYNEXIS INC	Award(A)	2,875	-	$0	Direct
Jan 8, 2026	TRVI Trevi Therapeutics, Inc.	Award(A) Stock Option (right to buy)	375,000	-	-	Direct
Jun 26, 2025	SCYX SCYNEXIS INC	Award(A)	23,000	-	-	Direct
Feb 14, 2025	ABUS Arbutus Biopharma Corp	Award(A)	90,100	-	-	Direct
Feb 4, 2025	ABUS Arbutus Biopharma Corp	Sale(S)	22,183	$3.28	$72,827	Direct

1-5 of 5 transactions

About HASTINGS DAVID C

HASTINGS DAVID C (SEC CIK 0001237401) files insider reports with the SEC as SCYNEXIS INC (SCYX), Chief Financial Officer of Trevi Therapeutics, Inc. (TRVI) and Chief Financial Officer of Arbutus Biopharma Corp (ABUS).

Signal8 holds 6 ownership filings by HASTINGS DAVID C (1 Form 3, 5 Form 4), filed between Feb 5, 2025 and Jun 30, 2026. Those filings report 5 transactions, from Feb 4, 2025 to Jun 26, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on HASTINGS DAVID C's filings is in NEW HAVEN, CT.

Recent filings by HASTINGS DAVID C

Jun 26, 2026: Grant or award of SCYX shares (Form 4, code A).
Jan 8, 2026: Grant or award of TRVI derivative securities (Form 4, code A).
Jun 26, 2025: Grant or award of SCYX shares (Form 4, code A).
Feb 14, 2025: Grant or award of ABUS shares (Form 4, code A).
Feb 4, 2025: Open-market sale of ABUS shares (Form 4, code S).

Other insiders filing for SCYNEXIS INC (SCYX)

Burke Steven Keith, Director
Subramanian Sanjay, Chief Financial Officer
Tinmouth Brian Philippe, Officer
Macdonald Guy, Officer
ANIDO ARMANDO, Officer
HANHAM ANN, Officer

How to read Form 4 transaction codes